Barrett's esophagus


Also found in: Acronyms, Wikipedia.

Barrett's esophagus

Gastroenterology A condition estimated to occur in ± 2 million Americans, which develops in Pts with GERD Definition Replacement of normal stratified squamous epithelium with metaplastic, premalignant intestinal columnar epithelium in the distal esophagus, ± accompanied by peptic ulceration, typically a sequel to chronic reflex; the degree of dysplasia correlates with aneuploidy by flow cytometry Endoscopy BE changes include a proximal migration of the squamocolumnar Z-line, and patchy areas corresponding to single layered columnar cells in intimate contact with underlying blood vessels; although most Pts are adults, BE may affect children, suggesting BE has a congenital component; BE carries a ± 35-40-fold ↑ risk of esophageal adenoCA, which is almost invariably accompanied by dysplasia, and has a prognosis similar to that of epidermoid carcinoma–14.5% 5-yr survival Management-restore normal squamous epithelium Electrocoagulation, argon plasma coagulation, laser therapy, laser + antireflux surgery, photodynamic therapy; thermal ablation of metaplastic esophageal mucosa has fallen into disfavor Low-grade dysplasia Follow-up, possibly β-carotene High-grade dysplasia Esophagectomy; endoscopic mucosal ablation, photodynamic therapy

Patient discussion about Barrett's esophagus

Q. Cn barret esophagous be cured? I was diagnosed with barretts esophagus several years ago, and so far keeps on the routine follow up. I met some other guy with same condition and he told after his doctor prescribed him with some anti-reflux meds, in the last endoscopy they found normal esophagus, and that he thinks he's now cured. Is that possible?

A. Anti-reflux treatment may lower the risk of cancer a little, but it won't cure it, so there's still a need for refular follow-up.

More discussions about Barrett's esophagus
References in periodicals archive ?
To reduce your risk of GERD and, thus, Barrett's esophagus, optimize your weight; minimize your consumption of alcohol, fatty, fried foods, caffeine, chocolate, alcohol, mints, citrus fruits and tomato-based products; refrain from eating large meals; and do not lie down within three hours of eating.
"We are pleased to have obtained FDA clearance to expand our indications for use to include Barrett's Esophagus with low grade dysplasia as an example of benign disease ablation as well as our present indication for Barrett's Esophagus with high grade dysplasia and malignant disease ablation," said Ellen Sheets MD, CEO and president of CSA Medical.
Barrett's Esophagus is a complication of Gastro Esophageal Reflux Disease (GERD) in which the tissue lining the esophagus changes form due to the presence of stomach acid on the tissue over time.
"This is called Barrett's esophagus." Although Barrett's esophagus is a benign condition, the cells can become abnormal (dysplasia), and may eventually turn cancerous.
C2 Therapeutics was founded in 2007 to address the limitations of current Barrett's esophagus treatment options.
Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
Gastroenterologists describe developments over the past few decades in the diagnosis and management of Barrett's esophagus and early esophageal adenocarcinoma.
Barrett's esophagus is in turn caused by gastroesophageal reflux disease (GERD), the rise of stomach juices.
Objective: Barrett's esophagus (BE) is the strongest risk factor of esophageal adenocarcinoma (EAC).
The findings from an animal study at the University of Pittsburgh School of Medicine could lead to new insights into the development and treatment of esophageal cancer and the precancerous condition known as Barrett's esophagus.
"These results directly challenge the established GERD-based Barrett's esophagus screening paradigm and provide strong rationale for using central obesity in Caucasian males with or without symptomatic GERD as criteria for Barrett's esophagus screening," Dr.
Barrett's esophagus (BE), an increasingly significant clinical condition in which metaplastic columnar epithelium replaces the normal distal esophageal squamous mucosa, is a complication of gas-troesophageal reflux disease (GERD).